Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07540754 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of May 2026 to May 26, 2026 · Secondary endpoints: details revised at 1 of 5 entries · Site details revisedv2 Show 3 more changesShow less
    • Start date changed from estimate of May 2026 to May 26, 2026
    • Secondary endpoints: details revised at 1 of 5 entries
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase I clinical study to compare the pharmacokinetics (PK) of HRS9531 Injection in participants with mild/moderate hepatic impairment and participants with normal hepatic function, and to evaluate the safety of HRS9531 Injection in these participants.
Trial Details
NCT Number NCT07540754
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Diabetes Mellitus, Weight Loss
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov